Research and Development Expenses Breakdown: Merck & Co., Inc. vs Amgen Inc.

A Decade of Innovation: R&D Spending in Pharma

In the competitive world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Merck & Co., Inc. and Amgen Inc. have been at the forefront, investing heavily in R&D to drive breakthroughs in medicine. From 2014 to 2023, Merck's R&D expenses surged by over 325%, peaking in 2023 with a staggering $30.5 billion. This represents a strategic commitment to innovation, as Merck consistently outpaced Amgen in R&D spending.
Amgen, while more conservative, maintained a steady increase in R&D investment, with a notable 34% rise from 2014 to 2023. Their peak spending occurred in 2021, reaching approximately $4.8 billion. This consistent investment underscores Amgen's dedication to advancing biotechnology.
The data highlights the contrasting strategies of these pharmaceutical giants, with Merck's aggressive investment reflecting a bold approach to innovation, while Amgen's steady growth emphasizes sustainable development.